Dermata Therapeutics Secures $1.5M Private Placement
Ticker: DRMAW · Form: 8-K · Filed: Jun 5, 2024 · CIK: 1853816
| Field | Detail |
|---|---|
| Company | Dermata Therapeutics, Inc. (DRMAW) |
| Form Type | 8-K |
| Filed Date | Jun 5, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $1.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financing, private-placement, r&d
Related Tickers: DRMA
TL;DR
DRMA just raised $1.5M via private placement to fund R&D, closing around June 11.
AI Summary
Dermata Therapeutics, Inc. announced on June 4, 2024, that it entered into a securities purchase agreement to sell approximately $1.5 million of its common stock and warrants in a private placement. The company expects to close this offering on or about June 11, 2024. This financing is intended to support ongoing research and development activities.
Why It Matters
This private placement provides Dermata Therapeutics with crucial funding to continue its development programs, potentially advancing its pipeline and future growth prospects.
Risk Assessment
Risk Level: medium — While the funding is positive, private placements can dilute existing shareholders and the success of the company still hinges on the efficacy of its R&D.
Key Numbers
- $1.5M — Private Placement Proceeds (Funds raised to support R&D activities.)
Key Players & Entities
- Dermata Therapeutics, Inc. (company) — Registrant
- June 4, 2024 (date) — Date of earliest event reported
- $1.5 million (dollar_amount) — Amount of private placement
- June 11, 2024 (date) — Expected closing date of offering
FAQ
What is the purpose of the private placement?
The proceeds from the private placement are intended to support ongoing research and development activities of Dermata Therapeutics, Inc.
When is the expected closing date for this offering?
The company expects to close the offering on or about June 11, 2024.
What type of securities are being sold in the private placement?
Dermata Therapeutics, Inc. is selling its common stock and warrants in the private placement.
What is the total amount raised in this private placement?
The company entered into a securities purchase agreement to sell approximately $1.5 million of its common stock and warrants.
What is the filing date of this Form 8-K?
This Form 8-K was filed as of June 5, 2024.
Filing Stats: 528 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-06-05 09:02:59
Key Financial Figures
- $0.0001 — ch Registered Common Stock, par value $0.0001 per share DRMA The Nasdaq Capital M
- $1.00 — ment to maintain a minimum bid price of $1.00 per share for continued listing on Nasd
Filing Documents
- drma_8k.htm (8-K) — 26KB
- 0001654954-24-007369.txt ( ) — 165KB
- drma-20240604.xsd (EX-101.SCH) — 6KB
- drma-20240604_lab.xml (EX-101.LAB) — 16KB
- drma-20240604_cal.xml (EX-101.CAL) — 1KB
- drma-20240604_pre.xml (EX-101.PRE) — 12KB
- drma-20240604_def.xml (EX-101.DEF) — 4KB
- drma_8k_htm.xml (XML) — 6KB
01 Other Events
Item 8.01 Other Events. As previously reported, on November 15, 2023, Dermata Therapeutics, Inc. (the "Company") received a letter from the Listing Qualifications Department (the "Staff") of the Nasdaq Stock Market LLC ("Nasdaq") indicating that based upon the closing bid price of the Company's common stock, par value $0.0001 per share, for the prior 30 consecutive business days, the Company was not in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement"). On May 14, 2024, the Company received a letter from the Staff of Nasdaq that the Company had been granted a 180-day extension through November 11, 2024, to regain compliance with the Minimum Bid Price Requirement. On June 4, 2024, the Company received a letter from the Staff of Nasdaq indicating that the Company has regained compliance with the Minimum Bid Price Requirement and the matter is now closed. 2 Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DERMATA THERAPEUTICS, INC. Dated: June 5, 2024 By: /s/ Gerald T. Proehl Gerald T. Proehl Chief Executive Officer 3